1 not yet recruiting, 1 recruiting, 1 terminated, 1 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow ALK Fusion Protein Expression: new trials by email Literature Review of ALK Fusion Protein Expression trials Research Report on ALK Fusion Protein Expression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC Peptide vaccine - NSCLC Stage IV, ALK Fusion Protein Expression | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2024-05-13 | 2026-07-28 |
| A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer Ensatinib, chemotherapy - ALK Fusion Protein Expression, Adjuvant Therapy | Phase 2 | Not yet recruiting | Sichuan University | 152 | 2022-01-01 | 2022-01-11 |
| Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) Data collection and quality of life questionnaire - Cancer, Cancer Metastatic | Unknown | Centre Leon Berard | 500 | 2021-06-22 | 2021-08-02 | |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression | Phase 2 | Withdrawn | Sameek Roychowdhury | 2019-03-20 | 2022-02-18 | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Capmatinib, Ceritinib, Entrectinib - ALK Fusion Protein Expression, BRAF wt Allele | Phase 2 | Terminated | University of California, San Francisco | 1 | 2015-03-26 | 2020-01-27 |
Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Brain Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Noonan Syndrome 6 (1)
Neoplasms (4) · Neoplasms by Site (4) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1)
Data Collection (1) · Drug Therapy (1) · Protein Subunit Vaccines (1) · brigatinib (1) · capmatinib (1) · ceritinib (1) · ensartinib (1) · entrectinib (1) · regorafenib (1)
Centre Leon Berard (1) · Sameek Roychowdhury (1) · Sichuan University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of California, San Francisco (1)
United States (3) · Austria (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Slovenia (1) · Spain (1) · United Kingdom (1)
Adil Daud (1) · Meijuan Huang, MD (1) · Sameek Roychowdhury, MD (1) · Vincent Lam, MD (1) · You Lu, MD (1)
P30CA016058 (1)